DNM1L and familial pancreatic carcinoma: The net effect of these three interventions (Drp1 inhibition, Mfn2 overexpression, or leflunomide) promoted mitochondrial fusion, which curbed oxidative phosphorylation (OXPHOS), thereby suppressing tumor growth in pancreatic cancer [3].